Abstract
Background
Goblet cell carcinoid (GCC) is a rare malignant tumor with distinct histological and clinical features. Our goals were to review the surgical and chemotherapy outcomes of patients with GCC.
Methods
We performed a retrospective review of the Mayo Clinic database from 1984 to 2004 with a prospective follow-up of 57 patients with GCC.
Results
The age at diagnosis (mean ± SE) was 55 ± 13 years. The most common presentations were right lower quadrant pain mimicking appendicitis (70%) and right lower quadrant or pelvic mass (25%). Only patients with T4 lesions had positive mesenteric nodes, with a frequency of 28%. Fifty percent of female patients had metastasis to the ovaries. The disease-specific 5-year survivals for stages I, II, III, and IV were 100%, 76%, 22%, and 14%, respectively; the overall mean survival was 47 ± 3 months. All stage I patients had simple appendectomy. The overall 5-year survival rates for patients with combined stages II to IV who underwent appendectomy versus right hemicolectomy were 43% and 34%, respectively (P = .604). The corresponding survival rates for adjuvant chemotherapy versus no chemotherapy were 32% and 27%, respectively (P = .151).
Conclusions
The prognosis for patients with GCC tumors correlates well with the American Joint Committee on Cancer stage at initial presentation. Appendectomy alone seems adequate for stage I disease. For staging purposes, right hemicolectomy is appropriate for T4 tumors or stage II to III disease provided that it can be performed with minimal risk. Surgical debulking is a consideration but is controversial. Adjuvant chemotherapy with 5-fluorouracil and leucovorin regimen is minimally effective against GCC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Subbuswamy SG, Gibbs NM, Ross CF, Morson BC. Goblet cell carcinoid of the appendix. Cancer 1974;34:338–44
Warner TF, Seo IS. Goblet cell carcinoid of appendix: ultrastructural features and histogenetic aspects. Cancer 1979;44:1700–6
Hofler H, Kloppel G, Heitz PU. Combined production of mucus, amines and peptides by goblet-cell carcinoids of the appendix and ileum. Pathol Res Pract 1984;178:555–61
Burke AP, Sobin LH, Federspiel BH, Shekitka KM. Appendiceal carcinoids: correlation of histology and immunohistochemistry. Mod Pathol 1989;2:630–7
Chen V, Qizilbash AH. Goblet cell carcinoid tumor of the appendix. Report of five cases and review of the literature. Arch Pathol Lab Med 1979;103:180–2
Berardi RS, Lee SS, Chen HP. Goblet cell carcinoids of the appendix. Surg Gynecol Obstet 1988;167:81–6
Anderson NH, Somerville JE, Johnston CF, Hayes DM, Buchanan KD, Sloan JM. Appendiceal goblet cell carcinoids: a clinicopathological and immunohistochemical study. Histopathology 1991;18:61–5
Butler JA, Houshiar A, Lin F, Wilson SE. Goblet cell carcinoid of the appendix. Am J Surg 1994;168:685–7
McCusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer 2002;94:3307–12
Varisco B, McAlvin B, Dias J, Franga D. Adenocarcinoid of the appendix: is right hemicolectomy necessary? A meta-analysis of retrospective chart reviews. Am Surg 2004;70:593–9
Del Campo JM, Felip E, Rubio D, et al. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol 1994;53:27–32
Hacker NF, van der Burg ME. Advanced ovarian cancer. Debulking and intervention surgery. Ann Oncol 1993;4(Suppl 4):17–22
Hosch WP, Rudi J, Stremmel W. Therapy of pseudomyxoma peritonei of appendiceal origin—surgical resection and intraperitoneal chemotherapy. Z Gastroenterol 1999;37:615–22
Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001;27:239–43
Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998;69:103–8
Zang RY, Zhang ZY, Li ZT, et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol 2000;75:24–30
Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2004;14:35–41
Smith JW, Kemeny N, Caldwell C, Banner P, Sigurdson E, Huvos A. Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1992;70:396–401
Beahrs OH, Henson, DE, Hutter RV, Kennedy BJ, eds. Handbook for Staging for Cancer: From the Manual for Staging of Cancer, 4th edition. American Joint Committee on Cancer, TNM Committee of the International Union Against Cancer. Philadelphia: JB Lippincott, 1993:89–93
Courtney M, Townsend DCS Jr. Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice. 17th ed. Philadelphia: Elsevier Saunders, 2004
Greenfield LJ, Mulholland MW, Oldham KT, Zelenock GB, Lillemoe KD, eds. Essentials of Surgery: Scientific Principles and Practice. Philadelphia: Lippincott-Raven, 1997
Lo NS, Sarr MG. Mucinous cystadenocarcinoma of the appendix. The controversy persists: a review. Hepatogastroenterology 2003;50:432–7
Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2003;13:764–70
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pham, T.H., Wolff, B., Abraham, S.C. et al. Surgical and Chemotherapy Treatment Outcomes of Goblet Cell Carcinoid: A Tertiary Cancer Center Experience. Ann Surg Oncol 13, 370–376 (2006). https://doi.org/10.1245/ASO.2006.02.016
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/ASO.2006.02.016